Format

Send to

Choose Destination
Ann Pharmacother. 2008 Mar;42(3):403-7. doi: 10.1345/aph.1K531. Epub 2008 Feb 26.

Use of intravenous valproic acid for acute migraine.

Author information

1
Internal Medicine, Akron General Medical Center, Akron, OH 44307, USA. lfrazee@agmc.org

Abstract

OBJECTIVE:

To review the literature regarding the use of intravenous valproic acid in aborting an acute migraine attack.

DATA SOURCES:

A MEDLINE (1967-June 2007) and bibliographic search of the English-language literature was conducted using the search terms valproic acid and migraine disorders.

STUDY SELECTION AND DATA EXTRACTION:

All articles identified through the search were included.

DATA SYNTHESIS:

Divalproex sodium is approved by the Food and Drug Administration for the prevention of migraine headaches. The use of intravenous valproic acid has been studied as a possible treatment for acute migraine. Available studies are small, mostly open-label and non-placebo-controlled, and used variable doses. Valproic acid has not been shown to be superior to comparator drugs and was inferior to prochlorperazine in one trial.

CONCLUSIONS:

Intravenous valproic acid has not been proven effective for acute migraine treatment. Future trials should be larger, placebo-controlled, and use a standardized dose and outcome measures.

PMID:
18303140
DOI:
10.1345/aph.1K531
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center